Therefore, it is necessary to analyze this topic and understand the immune function and molecular mechanism of METTL3 in esophageal cancer to explore whether METTL3 could become a new biomarker for immunotherapy of esophageal cancer and provide a new basis for immunotherapy and individualized treatment of ESCC patients. The gene discussed is METTL3; the disease is esophageal cancer.